New York, February 26, 2007 — Led by the strong growth of biotechnology drugs requiring novel delivery technologies, the injectable/implantable drug delivery market reached revenues of $9.8 billion in 2006, according to Drug Delivery Markets, Second Edition, Vol.2: Implantable/Injectable Delivery Systems, a new market research study from Kalorama Information.
The market is dominated by implantable, sustained-release, and targeted-injection drug delivery systems with manufacturer revenues of approximately $7.3 billion in 2006, an increase of 6.3% over 2002 sales. Growth continues to be fueled by the introduction of biological therapies, including blood modifiers and insulin products, with the sector projected to reach $9 billion by 2010.
Implantable technologies have been successfully utilized in administering anti-cancer therapeutics as well as the administration of high drug doses in traditionally inaccessible areas, such as the central nervous system, bone tissue, and beyond the blood–retinal barrier.
Also fueling growth is the needle-free sector with revenues expected to reach $3 billion by 2010. An expanding drug delivery marketplace, increasing consumer awareness, and growing focus on healthcare worker safety could help drive demand for needle-free systems.
The report accurately assesses the two-fold nature of the market, which encompasses drug delivery technology and the revenues earned from licensing that technology, as well as the pharmaceutical products that utilize the drug delivery technology. Revenues reported include pharmaceutical sales for products utilizing implant and injection technologies making Kalorama's market assessment the most well-rounded analysis of the entire market for injectable/implantable drug delivery.
"The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to significant improvements in drug delivery," notes Mary Anne Crandall, the report's author. "This is a dynamic market expected to increase at break-neck speed during the forecast period. Significant revenue increases are anticipated particularly in the needle-free delivery of injectable medications, especially in the vaccine arena."
Drug Delivery Markets, Second Edition, Vol.2: Implantable/Injectable Delivery Systems also includes extensive discussions of key trends and developments, in-depth company profiles of market leaders and niche players. It can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Drug-Delivery-Vol-1375771. It is also available at MarketResearch.com.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014, or visit www.KaloramaInformation.com.